Outcome and impact of post-remission strategy after MIDAM regimen in patients with relapsing or refractory acute myeloid leukemia

Salem Bahashwan^{1

2}, Cécile Moluçon-Chabrot^{1

2}, Eric Hermet^{1

2}, Aurélie Ravinet^{1

2}, Aurore Douge^{1

2}, Lauren Veronese^{1

3}, Andrei Tchirkov^{1

3}, Richard Lemal^{1

2}, Marc G Berger^{1

4}, Richard Veyrat-Masson^{1

4}, Olivier Tournilhac^{1

2}, Jacques-Olivier Bay^{1

2}, Romain Guièze^{1

2}

Affiliations

¹ Clermont Auvergne University, Clermont-Ferrand, France.
² Unit of Adult Cell Therapy and Clinical Hematology, University Hospital of Clermont-Ferrand, Clermont-Ferrand, France.
³ Cytogenetic Laboratory, University Hospital of Clermont-Ferrand, Clermont-Ferrand, France.
⁴ Department of Biology, University Hospital of Clermont-Ferrand, Clermont-Ferrand, France.

Free article

Salem Bahashwan et al. Am J Hematol. 2019 Jan.

Free article

. 2019 Jan;94(1):E32-E35.

doi: 10.1002/ajh.25332. Epub 2018 Nov 25.

¹ Clermont Auvergne University, Clermont-Ferrand, France.
² Unit of Adult Cell Therapy and Clinical Hematology, University Hospital of Clermont-Ferrand, Clermont-Ferrand, France.
³ Cytogenetic Laboratory, University Hospital of Clermont-Ferrand, Clermont-Ferrand, France.
⁴ Department of Biology, University Hospital of Clermont-Ferrand, Clermont-Ferrand, France.

No abstract available

Publication types